Ipsen
Clinical trials sponsored by Ipsen, explained in plain language.
-
Real-World data shows promise for kidney cancer drug combo
Disease control CompletedThis study observed 311 adults with advanced kidney cancer who received cabozantinib (a targeted therapy) plus nivolumab (an immunotherapy) as their first treatment. Researchers tracked how long patients lived and how long tumors stayed under control in real-world settings. The g…
Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New liposomal chemo cocktail takes on pancreatic cancer
Disease control CompletedThis Phase 3 trial tested a new combination of chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and leucovorin—against the standard treatment (nab-paclitaxel plus gemcitabine) in 770 people with metastatic pancreatic cancer who had not received prior chemother…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for kidney cancer patients after immunotherapy fails
Disease control CompletedThis study looked at whether the drug cabozantinib can help people with advanced kidney cancer that got worse after initial treatment with immunotherapy. 127 participants received cabozantinib as a second-line therapy. The main goal was to see how many patients experienced tumor …
Phase: PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New 6-Month shot shows promise for prostate cancer control
Disease control CompletedThis study tested a single injection of triptorelin pamoate that lasts 6 months in 195 Chinese men with advanced or metastatic prostate cancer. The goal was to lower testosterone to castrate levels, which helps slow cancer growth. Results showed the injection effectively reduced …
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 26, 2026 14:39 UTC
-
Botox vs dysport: which lasts longer for stiff muscles?
Symptom relief CompletedThis study compared two botulinum toxin injections, Dysport and Botox, in 464 adults with upper limb spasticity (stiff muscles in the arm). The goal was to see if Dysport is as safe as Botox and whether it provides a longer duration of effect. Participants received both treatment…
Phase: PHASE4 • Sponsor: Ipsen • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Liver study tests how palovarotene behaves in impaired patients
Knowledge-focused CompletedThis completed Phase 1 study looked at how moderate and severe liver impairment changes the way the body handles a single dose of palovarotene, compared to healthy people. Thirty-one participants were split into three groups based on liver function and received up to 10 mg of the…
Phase: PHASE1 • Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Wearable device tracks itch and sleep in rare liver disease
Knowledge-focused CompletedThis study tested a wearable sensor called ADAM to measure scratching and sleep patterns in 30 people with primary biliary cholangitis (PBC), a rare liver disease that often causes intense itching and poor sleep. Participants wore the sensor for 7 nights across four 7-day periods…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Study tracks quality of life in older prostate cancer patients on hormone therapy
Knowledge-focused CompletedThis study followed 831 men aged 60 and older with prostate cancer who were starting GnRH agonist therapy (a type of hormone therapy). Researchers measured how their quality of life changed over 6 months, comparing different age groups. The goal was to understand how age affects …
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
GripAble gadget tested for spasticity rehab after botox shots
Knowledge-focused CompletedThis study looked at whether a device called GripAble can help doctors and patients track the effects of Botox injections for arm muscle stiffness. Sixteen people with upper limb spasticity used the tool at home and during clinic visits. The goal was to see if it could measure ch…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:02 UTC